Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) shares dropped 4.7% on Thursday . The stock traded as low as $1.60 and last traded at $1.63. Approximately 8,474 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 1,564,620 shares. The stock had previously closed at $1.71.
Chromocell Therapeutics Price Performance
The firm’s 50 day moving average price is $1.39 and its two-hundred day moving average price is $0.96.
About Chromocell Therapeutics
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Further Reading
- Five stocks we like better than Chromocell Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- 3 Best Fintech Stocks for a Portfolio Boost
- DuPont’s Electronics Spinoff: The Start of Something Big
- Short Selling: How to Short a Stock
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
